Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Leadless ICD: Cameron Health's leadless S-ICD system, the first minimally invasive, subcutaneous implantable cardioverter defibrillator for the treatment of sudden cardiac arrest, detected 100% of induced and spontaneous episodes of irregular heart rhythms, according to data from four studies appearing online in the New England Journal of Medicine May 12, in conjunction with the HRS meeting. S-ICD implantation is simpler because it does not require transvenous lead insertion, the firm notes. "These studies suggest that the S-ICD System is a viable alternative that may overcome some of the problems associated with transvenous ICDs in certain patients," said Cameron Health co-founder and lead study author Gust Bardy, M.D., Seattle Institute for Cardiac Research. The firm began a pivotal trial March 18 to support U.S. approval of the device (1"The Gray Sheet" March 29, 2010)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel